| Title |
Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects
|
|---|---|
| Published in |
Clinical Drug Investigation, September 2013
|
| DOI | 10.1007/s40261-013-0128-3 |
| Pubmed ID | |
| Authors |
Rajendra H. Jani, Kevinkumar Kansagra, Mukul R. Jain, Harilal Patel |
| Abstract |
Dyslipidaemia is a major cardiovascular risk factor associated with type 2 diabetes mellitus. Saroglitazar (ZYH1) is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity. It has been developed for the treatment of dyslipidaemia and has favourable effects on glycaemic parameters in type 2 diabetes mellitus. The objective of this phase 1 study was to evaluate the pharmacokinetics, safety and tolerability of saroglitazar in healthy human subjects. |
Mendeley readers
The data shown below were compiled from readership statistics for 79 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Denmark | 1 | 1% |
| Unknown | 78 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 16% |
| Student > Bachelor | 9 | 11% |
| Student > Postgraduate | 7 | 9% |
| Student > Ph. D. Student | 6 | 8% |
| Student > Master | 5 | 6% |
| Other | 17 | 22% |
| Unknown | 22 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 20% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 13% |
| Nursing and Health Professions | 6 | 8% |
| Biochemistry, Genetics and Molecular Biology | 5 | 6% |
| Sports and Recreations | 5 | 6% |
| Other | 12 | 15% |
| Unknown | 25 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 January 2024.
All research outputs
#4,823,325
of 23,269,984 outputs
Outputs from Clinical Drug Investigation
#147
of 985 outputs
Outputs of similar age
#43,403
of 204,304 outputs
Outputs of similar age from Clinical Drug Investigation
#4
of 14 outputs
Altmetric has tracked 23,269,984 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 985 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.8. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 204,304 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.